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EMD in periodontal regenerative 
surgery modulates cytokine 
profiles: A randomised controlled 
clinical trial
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Staale P. Lyngstadaas1, Anne M. Aass2 & Janne E. Reseland1
The enamel matrix derivative (EMD) contains hundreds of peptides in different levels of proteolytic 
processing that may provide a range of biological effects of importance in wound healing. The aim of the 
present study was to compare the effect of EMD and its fractions on the cytokine profiles from human 
gingival fibroblasts in vitro and in gingival crevicular fluid (GCF) in a randomized controlled split-mouth 
clinical study (n = 12). Levels of cytokines in cell culture medium and in GCF were measured by Luminex 
over a 2-week period. In the clinical study, levels of pro-inflammatory cytokines and chemokines were 
increased, whereas the levels of transforming growth factor-α (TGF-α) and platelet-derived growth 
factor-BB (PDGF-BB) were reduced. The in vitro study showed that EMD and its high and low molecular 
weight fractions reduced the secretion of pro-inflammatory cytokines and chemokines compared 
to untreated cells. EMD had an effect on levels of cytokines related to fibroplasia, angiogenesis, 
inflammation and chemotaxis both in vitro and in vivo, however, the anti-inflammatory effect induced 
by EMD observed in the in vitro study could not be confirmed clinically.
Several studies have demonstrated that enamel matrix proteins, in particular amelogenin, applied to the root 
surface during periodontal surgery promote periodontal regeneration in pre-clinical1 and in clinical studies2. 
Clinical studies on enamel matrix proteins have focussed on healing periods varying between 6 months and 3 
years2,3. Early healing events are critical and dictate the type of tissue that will develop later1,4,5. Histological stud-
ies6 have suggested that enamel matrix proteins are detectable on the denuded tooth root surface for 2–4 weeks 
following surgery. This seems to be a sufficiently long period of time to permit recolonization of periodontal 
ligament cells, initiate regenerative pathways and inhibit the down growth and proliferation of epithelial cells4. 
It is crucial to understand early healing mechanisms and use the knowledge gained to develop improved thera-
peutic strategies to promote regrowth of periodontal tissues lost due to disease. Moreover, clinical reports have 
suggested that enamel matrix proteins lead to improved early soft tissue wound healing7,8. Based on these clinical 
observations, it has been suggested that EMD may have an effect on gingival fibroblasts; relevant cells in soft tis-
sue wound healing9. The gingival connective tissue is the oral equivalent to the dermis of the skin, and the main 
residing fibroblast is the gingival fibroblast10. Fibroblasts have a central role in wound healing as they do not only 
produce and organize the ECM11–13 but are also able to regulate inflammation through chemokine and cytokine 
expression14, angiogenesis15, and re-epithelialization16,17. EMD-induced cytokine release on gingival fibroblasts 
during the early healing period contribute to a possible favourable early wound healing effect18 or even play a role 
in the subsequent EMD-mediated regeneration of the tissues.
Several in vitro studies have provided valuable information on the molecular mediators induced by EMD19,20. 
In periodontal ligament (PDL) fibroblasts, EMD increased interleukin-6 (IL-6), TGF-β 1 and PDGF-AB pro-
duction21 and reduced IL-4 gene expression22. In an extensive analyses of cytokines secreted from PDL cells23, 
higher molecular weight fractions of EMD were found to induce an increase in vascular endothelial growth factor 
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(VEGF) and IL-6 secretion, whereas lower molecular weight fractions enhanced cell proliferation and secretion 
of IL-8 and monocyte chemoattractant protein-1 (MCP-1) and reduced IL-4 release.
In vitro studies are often used as models to indicate and evaluate molecular mechanisms of clinical treatment strat-
egies. GCF components have been studied with the aim of using them as predictors of periodontal disease progression 
and healing after therapy24, but with little success24. It is likely that a diagnostic model utilising a broader spectrum of 
GCF components would have a greater predictive power compared to models based on few components.
The aim of the present study was to assess and compare the effect of enamel matrix derivative (EMD) on the 
cytokine profiles from human gingival fibroblasts in vitro and, clinically, in gingival crevicular fluid during early 
periodontal wound healing. In addition, the bioactivity of various fractions of EMD was evaluated in vitro to 
identify active components.
Results
Clinical study. An overview of the cytokine profile induced by EMD and control groups is shown in Table 1. 
There were no adverse events or discomforts associated to the EMD or the control group. There were no signifi-
cant differences between EMD- and control-treated sites at baseline for any of the cytokines measured.
TGF-α was significantly lower in both control (p = 0.0001) and EMD (p = 0.0001) at day 7 compared to base-
line TGF-α levels. At day 14, TGF-α values were also significantly reduced in both the control (p = 0.022) and 
EMD (p = 0.003) groups compared to baseline values. There were no significant differences between the groups 
at any time point studied (Fig. 1b).
IL-4 levels in GCF were reduced in both the test and control group at day 7 compared to baseline values, 
however, it was only significantly changed (p = 0.014) for the control group. There were no significant differences 
between the two groups at day 7 and day 14. (Fig. 1e).
IL-6 was enhanced 50-fold in EMD-treated sites (p < 0.0001) and 25 fold in the control group (p < 0.0001) com-
pared to baseline values at day 7. The difference between groups did not reach statistical significance. At day 14, IL-6 
was also significantly increased 12-fold and 5-fold in EMD (p = 0.009) and control groups (p < 0.0001) respectively, 
compared to baseline values. There were no significant differences between the groups at any time point (Fig. 1f).
Day 7
Range 
day 7 Day 14
Range 
day 14
EMD
↑ Total protein 5227.14 ↑ Total protein 4362.86
↓ TGF-α # 0.03 ↓ TGF-α# 0.05
↓ IFN-γ 0.01 ↑ IFN-γ 0.01
↑ MDC 0.01 ↑ MDC 0.20
↓ IL-4 0.03 ↑ IL-4 0.03
↑ IL-6# 0.40 ↑ IL-6# 0.21
↑ IL-8# 3.80 ↑ IL-8#,* 1.18
↑ PDGF-AA 0.02 ↑ PDGF-AA 0.06
↓ PDGF-BB 0.12 ↓ PDGF-BB* 0.12
↓ IP-10 0.03 ↑ IP-10 0.14
↑ MCP-1 0.05 ↑ MCP-1 0.06
↑ TNF-α# 0.02 ↑ TNF-α 0.08
↓ VEGF 0.15 = VEGF 0.38
CONTROL
↑ Total protein 6400.00 ↑ Total protein 5531.43
↓ TGF-α# 0.05 ↓ TGF-α# 0.06
↓ IFN-γ 0.01 ↑ IFN-γ 0.04
↑ MDC 0.02 ↑ MDC 0.21
↓ IL-4# 0.03 ↑ IL-4 0.10
↑ IL-6# 0.51 ↑ IL-6# 0.11
↑ IL-8# 2.12 ↑ IL-8#,* 0.94
↑ PDGF-AA 0.05 ↑ PDGF-AA 0.16
↓ PDGF-BB 0.10 ↑ PDGF-BB* 0.25
↓ IP-10# 0.04 ↑ IP-10 0.27
↑ MCP-1 0.03 ↑ MCP-1 0.03
↑ TNF-α# 0.08 ↑ TNF-α# 0.03
↓ VEGF 0.24 ↑ VEGF 0.71
Table 1.  Cytokine profile induced by EMD- and controlled-operated sites during early periodontal wound 
healing. Cytokines after symbol ↑ , ↓ or = mean that they are increased, decreased or constant respectively based 
on mean values of fold changes compared to baseline cytokine levels. Total protein values are given in μg ml−1. 
Cytokine levels are given in pg cytokine μg total protein−1. The range is calculated from changes with respect to 
baseline levels. Only statistically significant changes marked with * or # define whether a cytokine is changed. 
#Significant intra-group differences compared to baseline cytokine levels (p < 0.05). *Significant inter-group 
differences at day 7 or day 14 (p < 0.05) (n = 12 patients).
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Interestingly, EMD-treated sites presented significantly increased levels of IL-8, around 25-fold (p < 0.0001) 
at day 7 and 5-fold (p = 0.006) at day 14 compared to baseline values. The control group also presented signifi-
cantly increased levels of IL-8, around 11-fold (p < 0.0001) at day 7 and 2-fold (p < 0.0001) at day 14 compared 
Figure 1. Box plot of GCF normalized cytokine levels (pg cytokine/μg total protein) at baseline, day 7 and  
day 14. (a) Total protein, (b) TGF-α , (c) IFN-γ , (d) MDC, (e) IL-4, (f) IL-6, (g) IL-8, (h) PDGF-AA, (i) PDGF 
-BB, (j) IP-10, (k) MCP-1, (l) TNF-α , (m) VEGF. #Significant intra-group differences in cytokine levels between 
baseline and day 7 or day 14 (p < 0.05). *Significant inter-group differences in cytokine levels between control 
and EMD sites (p < 0.05). Generalized estimating equations (GEE) (n = 12 patients). Box plots show the 
median, the 25th and 75th percentiles, Tukey whiskers (median ± 1.5 times interquartile range), and outliers (• ).
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to baseline values. Significant inter-group differences were found at day 14 with EMD-treated sites having a more 
pronounced effect on IL-8 release than in the control group (p = 0.030) (Fig. 1g).
PDGF-BB levels in GCF were significantly decreased in EMD both at day 7 (p = 0.001) and day 14 (p = 0.021) 
compared to baseline levels. By contrast, PDGF-BB levels in control sites were significantly reduced at day 7 
(p = 0.001) and were increased twice at day 14, although this increase was not significant. EMD-treated sites 
significantly decreased PDGF-BB levels at day 14 compared to the control sites (p = 0.042) (Fig. 1i).
TNF-α release was significant at day 7 in the EMD and control groups, with an increase of 3-fold (p = 0.044) 
and 4-fold (p = 0.021) respectively, compared to baseline values. The release of TNF-α was also significantly 
enhanced 3-fold in the control group (p < 0.0001) at day 14 compared to baseline values. There were no differ-
ences between groups at any time point (Fig. 1l).
IP-10 release was unchanged at day 7 in both groups. A significant intra-group difference was found at day 7 in 
the control group compared to baseline values (p = 0.013). There were no significant differences between groups 
at any time point (Fig. 1j).
There were no significant intra-group or inter-group differences for total protein, IFN-γ , MDC, PDGF-AA, 
MCP-1 and VEGF at any of the time points assessed.
In vitro study. An overview of changes in cytokine levels for the different fractions is given in Table 2. In 
contrast to clinical findings, EMD reduced the IL-6, IL-8 and VEGF secretion compared to untreated gingival 
fibroblasts during the first week of the experiment.
Similarly, both high and low molecular weight fractions of EMD reduced IL-6, IL-8, VEGF and MCP-1 secre-
tion compared to untreated cells over the 2-week study period. No differences between high and low molecular 
weight fractions were observed in terms of inducing cytokine secretion.
The anti-inflammatory cytokine profile obtained by the various fractions in the in vitro study could not be 
confirmed clinically.
While IL-4, IP-10, TNF-α and IFN-γ levels could be detected in GCF in the clinical study, these cytokines 
were below the detection limit for the assay and for all treatment groups at all time points in the in vitro study. 
Other cytokines that were below the detection limit in the in vitro study were: G-CSF, IL-7 and RANTES.
Discussion
The observed effect of EMD on the various cytokines secreted from gingival fibroblasts in vitro was not replicated 
in GCF from treated periodontal patients. The discrepancy between the in vitro and clinical results may be related 
to contribution of factors from more than one cell type in GCF. In addition, the EMD used in the clinical study 
was from a different lot number than the EMD used in vitro and being a biologically derived product, the content 
of EMD might vary between different batches. Differences among lots of EMD will have to be determined.
TGF-α levels in GCF were reduced in both control and EMD treated sites compared to baseline values over 
the 2-week study period. TGF-α plays an important role in the proliferative phase of wound healing as it stim-
ulates epidermal regrowth, angiogenesis and granulation tissue formation25–27. Nonetheless, TGF-α has been 
shown to be significantly reduced in patients with periodontal disease compared to healthy patients28. Altered 
TGF-α secretion in periodontitis patients may affect periodontal wound healing.
Gingival 
fibroblasts Day 1 Day 3 Day 7 Day 14
EMD ↓ IL6** ↓ VEGF* ↓ IL8**
F1 ↓ IL8**, VEGF** ↓ IL6***, IL8** ↓ IL6**, IL8**, MCP1**, VEGF*
F2 ↓ IL6**, MCP1**, VEGF*** ↓ IL6**, IL8**, MCP1**
F3 ↓ VEGF** ↓ VEGF*** ↓ MCP1**
F4 ↓ IL6***, IL8**, MCP1***, VEGF***
F5 ↓ IL6**, IL8**, MCP1**, VEGF** ↓ IL6**, VEGF** ↓ IL6***, MCP1**
F6 ↓ IL6** ↓ IL6***, IL8**, VEGF*** ↓ IL6** ↓ IL6***, IL8***, MCP1***, VEGF**
F7 ↓ IL6**, IL8***, MCP1**, VEGF*** ↓ IL8**, MCP1** ↓ IL6**
F8 ↓ VEGF**
F9 ↓ IL6***, IL8***, MCP1*** ↓ IL6**, IL8**, MCP1***, VEGF**
F10 ↓ VEGF*
F11
F12 ↓ VEGF*
F13
Table 2.  Cytokine levels in cell culture medium from gingival fibroblasts incubated with EMD and EMD 
fractions (F1–F13) relative to untreated control at the same timepoint. EMD: enamel matrix derivative. IL-6: 
interleukin-6; IL-8: interleukin-8; MCP-1: monocyte chemoattractant protein-1; VEGF: vascular endothelial 
growth factor. ↓ mean that cytokine levels are significantly reduced compared to the control group. Fractions 
1–6 shared components above or around 20 KDa, whereas fractions 7–13 contained components below 5 kDa. 
*p < 0.05, **p < 0.01, ***p < 0.001 (n = 3).
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Among all cytokines analyzed, the pro-inflammatory cytokines IL-6 and IL-8 were the cytokines most influ-
enced by periodontal surgery in both EMD and control sites. Levels of these two cytokines are elevated during 
the inflammatory phase of wound healing29,30. Engelhardt et al.29 demonstrated enhanced IL-8 expression in the 
superficial wound bed that correlated spatially and temporally with neutrophil infiltration. Galluci et al.30 identi-
fied IL-6 expression in the epithelial wound edge and in macrophages and fibroblasts of the dermis.
In the in vitro study, EMD and its fractions induced a reduced secretion of pro-inflammatory factors. This 
observation is in line with Nokhbehsaim et al.31 who found that EMD downregulated IL-1β , IL-6 and IL-8 expres-
sion in PDL cells. A reduction of IL-6, IL-8 and MCP-1 secretion during the early phase of healing might lead to 
a reduced migration of inflammatory cells at the wound site32–34. In contrast, EMD and its fractions have been 
found to enhance the secretion of IL-6, IL-8 and MCP-1 in PDL fibroblasts23. This discrepancy might be explained 
by the difference in characteristics and functions of these cells35. EMD contains hundreds of peptides in different 
levels of proteolytic processing that may provide a range of biological effects of importance in wound healing23. It 
is possible that the effect of EMD in wound healing and regeneration may be related to a single component or, on 
the other hand, its effect may be caused by its composition as a whole, or a range of molecular weight components. 
This question remains unanswered in the literature. There are difficulties to characterize EMD because, upon size 
fractionation, the same proteins may be found in several fractions23. There is the possibility that a purified bioac-
tive component can be characterized and thus an improved EMD formulation may be developed.
Reports from clinicians have claimed that early wound healing is characterized by a reduced inflammation in 
the gingival soft tissue7,8. The observed increase in pro-inflammatory cytokines in GCF may indicate contribution 
from other sources than gingival fibroblasts.
The total GCF protein content was increased, however, this did not reach significance compared to baseline 
values. Total protein has been shown to increase with gingival inflammation36,37. Giannopoulou et al.38 showed 
that after non-surgical periodontal therapy, total protein significantly decreased. This was accompanied with a 
decrease in clinical signs of inflammation38. Thus, it is expected that the total protein would increase during the 
early inflammatory phase of wound healing.
Villa et al.23 found that most enamel matrix derived fractions induced a decreased secretion of IL-4 in PDL 
fibroblasts compared to untreated cells. In the present clinical study, IL-4 secretion was decreased in both EMD 
and control groups compared to baseline levels, but only reached significance in the control group.
PDGF-AA levels were increased in both the control and EMD groups over the study period, although none 
of these effects were significant neither in the intra-group nor in the inter-group analyses. By contrast, PDGF-BB 
levels were significantly reduced by EMD compared to baseline values. This pattern was not found for the control 
group. It has been suggested that PDGF-A chains might play a role in periodontal wound healing during the first 
days of healing and PDGF-B chains might become more relevant in the wound bed later, correlating with fibro-
blast induced collagen synthesis that takes place after week 139.
Examples where no significant changes in cytokine levels between test and control groups were observed may 
be related to high variation between individuals40 and the relatively low number of patients. Another issue to 
take into account is that some of the inflammatory cytokines analyzed might be constitutively overproduced in 
periodontitis lesions41. Thus, high levels of these cytokines might already be present at baseline and also during 
wound healing. This might explain why some cytokines might not show differences over time or between groups. 
It is generally accepted that the intra- and inter-assay variation should be below 15%42. 3 cytokines presented an 
inter-assay variation above 15%: IP-10 (15.3%), PDGF-AA (16.7%) and IL-6 (18.3%). Thus, the results have to be 
interpreted cautiously.
This study had a split-mouth design. An important drawback of such a design is the possibility of a 
carry-across effect43. The results have to be interpreted carefully as this type of design can lead to reduced treat-
ment differences, and estimates of the treatment effect from split-mouth and parallel designs may not be the 
same43.
The most preferred strategy for collecting GCF is by use of paper strips. In the present study paper points 
were used. To our knowledge there is no evidence to support the use of paper strips over paper points to collect 
GCF. In one study44, paper strips showed higher levels of cytokines and a higher recovery rate than paper points. 
Nonetheless, these factors also depend on paper composition45 and binding properties of different cytokines 
which may be influenced by factors such as hydrophobicity, charge and structure44.
A common problem in GCF analyses is the low volume collected, which precludes the analyses of multiple 
cytokines46,47. Modern multiplexing methods such as Luminex require low sample volumes, are highly sensitive, 
and allow the analyses of up to 100 analytes simultaneously in one sample, a great advantage compared to meth-
ods measuring individual analytes (e.g. ELISA). Identification of cytokine profiles may increase the predictability 
of regenerative procedures. Future studies should establish which cytokine profiles are associated with regenera-
tive outcomes and which profiles are related to unfavourable outcomes.
To the best of our knowledge this is the first report that simultaneously assesses cytokine secretion from 
human gingival fibroblasts and gingival crevicular fluid after the administration of EMD. In this report we are 
suggesting some mechanisms underlying the possible early healing effect of EMD. The assessment of postopera-
tive healing with an adequate healing index3 and a cytokine profile might predict regenerative outcomes.
Conclusions
From the findings of the present study and previously published work23, EMD may promote improved early 
wound healing with reduced gingival fibroblasts induced inflammation. The regenerative capabilities of EMD 
might be mediated through its influence on PDL fibroblasts. The anti-inflammatory cytokine profile observed 
in vitro could not be confirmed clinically. In addition, EMD affects growth factors and cytokines related to fibro-
plasia, angiogenesis, inflammation and chemotaxis both in vitro and in vivo.
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Material and Methods
Clinical study. The clinical study was designed as a randomised controlled split-mouth clinical trial. The 
study protocol was approved by the Regional Committee for Research Ethics, Oslo, Norway (2013/1827/REK sør-
øst C), and patients signed an (approved) informed consent form before entering the study. The investigation was 
performed according to the principles of the Declaration of Helsinki on experiments involving human subjects. 
The presence of biological markers in the GCF was assessed at baseline, and one and two weeks postoperatively.
Patients. Subjects undergoing elective periodontal treatment at a private periodontal specialist clinic were 
included in the present study. Fifteen patients aged 25–75 years suffering from generalized severe chronic perio-
dontitis were recruited during the first trimester of 2014 and treated during the period between April and August 
of 2014. Three subjects that required grafting procedures were excluded from the study and one patient did not 
attend the surgery for the control site, leaving a total number of 11 sites for the control group and 12 sites for the 
EMD treated group. Adverse events were evaluated and recorded at each visit. All patients had undergone an ini-
tial causative treatment phase consisting of patient motivation, oral hygiene instruction and supra-, subgingival 
scaling and root planing. Patients were re-evaluated six weeks after scaling and root planning and scheduled for 
surgery as appropriate. Baseline measurements at the test and control sites were obtained on the day of surgery. 
Baseline defect characteristics are presented in Table 3.
Inclusion criteria and exclusion criteria for participation in the study. The inclusion criteria were based on the 
presence of two similar periodontal defects in different quadrants with clinical attachment loss of at least 5 mm, 
probing pocket depth of 6 mm or more, horizontal and/or vertical bone loss as demonstrated by the probing 
measurement and radiographic assessments following the initial phase of periodontal treatment. Experimental 
teeth must either have exhibited a vital pulp or, if subjected to root canal treatment, be asymptomatic.
Exclusion criteria were smoking, patients having used antibiotics in the 6 months prior to treatment, patients 
with disorders that compromise wound healing, such as diabetes mellitus, cancer, HIV, chronic high dose ster-
oid therapy, radiation or immune-suppressive therapy and patients with acute infectious lesions in the area of 
intended therapy.
Surgical intervention. Clinical measurements were obtained at baseline. Full-thickness mucoperiosteal flaps 
were elevated on the buccal, lingual and interproximal aspects of the involved teeth. Granulation tissue adherent 
to the alveolar bone was removed. Remaining subgingival calculus was removed with curettes. Following open 
flap debridement, teeth were randomly assigned to receive either the test or the control treatment by the tossing of 
a coin. In the test sites, EMD in propylene glycol alginate (Emdogain; Straumann, Basel, Switzerland) was directly 
applied to the exposed alveolar bone as well as onto the root surfaces. Flaps were repositioned and tension-free 
primary closure of the wound was achieved by means of single non-resorbable sutures (Propylen 5.0; Medipac, 
Kilkis, Greece). Control sites received the same surgical procedure but without the application of Emdogain. 
Sutures were removed after 14 days. Patients were advised to rinse twice daily with a 0.2% solution of chlorhex-
idine digluconate (Corsodyl; GlaxoSmithKline, Münchenbuchsee, Germany) for 2 weeks. No antibiotics were 
given48,49, and mechanical oral hygiene was not allowed in the surgical areas during this period. Analgesics were 
taken by the patients on an as needed basis.
Variable EMD (n = 12) CONTROL (n = 11) P value
PPD at deepest defect (mm) 7.0 (6, 8) 7.0 (6, 8) n.s.
CAL at deepest defect (mm) 6.0 (5, 8) 6.0 (6, 7) n.s.
Deepest infrabony defect (mm) 2.5 (0, 8) 2.0 (0, 5) n.s.
Total protein (μg ml−1) 975.57 (4475.71) 1307 (2802.86) n.s
TGF-α (pg ml−1) 28.04 (94.25) 22.3 (64.03) n.s.
IFN-γ (pg ml−1) 2.47 (4.65) 3.2 (10.1) n.s.
MDC (pg ml−1) 7.39 (116.75) 8.3 (14.08) n.s.
IL-4 (pg ml−1) 12.04 (17.88) 15.16 (29.32) n.s.
IL-6 (pg ml−1) 7.61 (50.66) 13.46 (37.29) n.s.
IL-8 (pg ml−1) 96 (1581.8) 186 (422.67) n.s.
PDGF-AA (pg ml−1) 9.6 (73.35) 11.84 (30.13) n.s.
PDGF-BB (pg ml−1) 77.09 (189.93) 80.74 (186.79) n.s.
IP-10 (pg ml−1) 7.63 (96.26) 11.7 (31.81) n.s.
MCP-1 (pg ml−1) 12.64 (40.02) 11.37 (26.95) n.s.
TNF-α (pg ml−1) 6.28 (39.09) 7.18 (22.48) n.s.
VEGF (pg ml−1) 116.02 (819.13) 131.92 (193.36) n.s.
Table 3.  Baseline characteristics of the periodontal defects. Clinical data given as median (min, max). 
Cytokine baseline levels data given as median (range). Cytokine levels were normalized to total protein (pg 
cytokine μg total protein−1). PPD: probing pocket depth. CAL: clinical attachment level. Comparisons between 
EMD and control treated sites. Clinical parameters analysed by Mann-Whitney U test. Cytokine parameters 
analysed by GEE; n.s. (non- significant).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:23060 | DOI: 10.1038/srep23060
Gingival crevicular fluid (GCF) sampling. GCF samples were obtained from both test and control sites at base-
line, day 7 and day 14 post-surgery as previously described50. Multiplex analyses of the level of cytokines in GCF 
was performed as previously described50. The experimental sites were isolated with cotton rolls, and GCF was col-
lected using endodontic paper points ISO size 50 (Beutel rock VDW; München, Germany) in the gingival sulcus 
for 10 seconds at the experimental sites of control and test teeth. The paper points were transferred to Eppendorf 
microtubes (Axygen, Tewksbury, MA, USA) and were coded with a unique identifier. Samples were immediately 
frozen at − 20 °C after collection, and transferred and stored at minus 80 °C until analysis.
Protein quantification from gingival crevicular fluid. All laboratory analyses were performed blind with respect 
to sample identification, visit and patient information. Tris-buffered saline (TBS; 200 μl) was added to each tube 
containing GCF samples. Multianalyte profiling of the level of cytokines was performed on the Luminex-200 
system (Luminex, Austin, TX, USA). The levels were monitored related to the amount of total protein in each 
sample. The amount of TGF-α , interferon-γ (IFN-γ ), human macrophage-derived chemokine (MDC/CCL22), 
PDGF-AA, PDGF-BB, IL-4, IL-6, IL-8, interferon-γ induced protein (IP-10), MCP-1, tumor necrosis factor-α 
(TNF-α ), and VEGF, was measured using the human cytokine/chemokine kit (Milliplex human cytokine 
MPXHCYTO-60k, Millipore, Billerica, MA, USA). All analyses were performed according to the manufacturers’ 
protocols. The intra-assay and inter-assay variation for the cytokines analyzed ranged between 1.5 and 18.3%.
The total protein content in GCF was determined using the BCA protein assay kit (Pierce, Rockford, IL, USA) 
following the manufacturer’s kit instructions.
In vitro study. Cell cultures. Commercially available human gingival fibroblasts (ATCC, Manassas, VA, 
USA) were grown in Dulbecco’s modified Eagle’s medium (High Glucose 4.5 g/l, PAA laboratories, Linz, Austria) 
supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 μg/ml Streptomycin (PAA labora-
tories). Cells were subcultured at 37 °C in a humidified atmosphere of 10% CO2 according to the manufacturer’s 
instructions.
EMD fractions. Fractions were obtained as described previously23. Briefly, EMD (Biora, Malmö, Sweden) 
was subjected to size-exclusion chromatography using a 90 × 1.6-cm column of Bio Gel P10 (Bio-Rad, Hemel 
Hempstead, UK). Proteins were eluted using 0.125 M formic acid and the column eluent was monitored at 280 nm 
and 5-ml fractions were collected and freeze dried. The cultured cells were treated with either EMD or the various 
fractions reconstituted in cell culture medium at molar concentrations equivalent to their content in 10 μg ml−1 of 
whole EMD. Untreated cells were used as controls. Three replicate experiments were conducted for every fraction, 
EMD and the controls. Cell culture media was harvested after 1, 3, 7 and 14 days. The fractions were characterized 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and liquid chromatography electro-
spray ionization–tandem mass spectrometry as previously described23.
Protein quantification in cell culture medium. Multianalyte profiling of the level of cytokines in concentrated 
cell culture medium of gingival fibroblasts was performed on the Luminex-200 system (Luminex) as previously 
described23. The amount of granulocyte colony-stimulating factor (G-CSF), IL-4, IP-10, TNF-α , IFN-γ , IL-6, 
IL-7, IL-8, MCP-1, regulated upon activation of normal T-cell expressed and secreted (RANTES) and VEGF was 
measured using the human cytokine/chemokine kit (Milliplex human cytokine MPXHCYTO-60k; Millipore). 
The intra-assay variation for the analyzed cytokines varied between 1.5 and 4.3%. The inter-assay variation varied 
between 3.5% and 18.3%.
Statistical analysis. Sample size calculation was not performed, as this study was a pilot to assess the 
effect of EMD on multiple cytokines after periodontal surgical therapy. For the clinical study, cytokine 
concentrations were normalized to total protein (pg of cytokine μg total protein−1) and served as the 
primary outcome. Generalized estimating equations were used to adjust for clustering within subjects in 
a split-mouth design and to investigate the interaction between GCF cytokine levels (dependent variable) 
and time or treatment group (independent factors). Thus, inter-group comparisons in cytokine levels were 
made at each time point and intra-group comparisons in cytokine levels were made to baseline values at 
day 7 and day 14. This statistical analyses was performed with SPSS for Mac (version 21; SPSS, Chicago, 
IL, USA) (Supplementary Dataset).
For the in vitro study, statistical comparison between treatment groups and controls was performed using 
parametric one-way analysis of variance (ANOVA) and post-hoc Dunnet’s test with multiple comparisons 
towards the untreated control group. When the normality test failed, ANOVA on ranks (Kruskal Wallis test) and 
post-hoc Dunn’s test was performed. (SigmaStat software; Systat, San Jose, CA, USA). P ≤ 0.05 was considered 
significant.
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